StreetInsider.com News Articles

Lupin Receives Approval from U.S. FDA for Ranluspec™(ranibizumab) Injection

Thu, 04 Jun 2026 16:39:00 -0400

MUMBAI, India and NAPLES, Fla., June 4, 2026 /PRNewswire/ -- Global pharmaceutical leader Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that the United States Food and Drug Administration (U.S. FDA) has approved its ranibizumab, Ranluspec™ (ranibizumab-hkdz), as an interchangeable biosimilar referencing to Lucentis® (Genentech).

Ranluspec™ is the only interchangeable biosimilar ranibizumab approved in the United States in both vials and pre-filled syringes

Lupin Receives Approval from U.S. FDA for Ranluspec™(ranibizumab) Injection

Thu, 04 Jun 2026 16:39:00 -0400

Ranluspec™ is the only interchangeable biosimilar ranibizumab approved in the United States in both vials and pre-filled syringes

Lupin Receives Approval from U.S. FDA for Ranluspec™(ranibizumab) Injection

Thu, 04 Jun 2026 16:39:00 -0400

Ranluspec™ is the only interchangeable biosimilar ranibizumab approved in the United States in both vials and pre-filled syringes

Lupin Receives Approval from U.S. FDA for Ranluspec™(ranibizumab) Injection

Thu, 04 Jun 2026 16:39:00 -0400

Ranluspec™ is the only interchangeable biosimilar ranibizumab approved in the United States in both vials and pre-filled syringes

Lupin Receives Approval from U.S. FDA for Ranluspec™(ranibizumab) Injection

Thu, 04 Jun 2026 16:39:00 -0400

Ranluspec™ is the only interchangeable biosimilar ranibizumab approved in the United States in both vials and pre-filled syringes

Lupin Receives Approval from U.S. FDA for Ranluspec™(ranibizumab) Injection

Thu, 04 Jun 2026 16:39:00 -0400

Ranluspec™ is the only interchangeable biosimilar ranibizumab approved in the United States in both vials and pre-filled syringes

Lupin Receives Approval from U.S. FDA for Ranluspec™(ranibizumab) Injection

Thu, 04 Jun 2026 16:39:00 -0400

Ranluspec™ is the only interchangeable biosimilar ranibizumab approved in the United States in both vials and pre-filled syringes

Lupin Receives Approval from U.S. FDA for Ranluspec™(ranibizumab) Injection

Thu, 04 Jun 2026 16:39:00 -0400

Ranluspec™ is the only interchangeable biosimilar ranibizumab approved in the United States in both vials and pre-filled syringes

Lupin Receives Approval from U.S. FDA for Ranluspec™(ranibizumab) Injection

Thu, 04 Jun 2026 16:39:00 -0400

Ranluspec™ is the only interchangeable biosimilar ranibizumab approved in the United States in both vials and pre-filled syringes

Lupin Receives Approval from U.S. FDA for Ranluspec™(ranibizumab) Injection

Thu, 04 Jun 2026 16:39:00 -0400

Ranluspec™ is the only interchangeable biosimilar ranibizumab approved in the United States in both vials and pre-filled syringes

Lupin Receives Approval from U.S. FDA for Ranluspec™(ranibizumab) Injection

Thu, 04 Jun 2026 16:39:00 -0400

Ranluspec™ is the only interchangeable biosimilar ranibizumab approved in the United States in both vials and pre-filled syringes

Lupin Receives Approval from U.S. FDA for Ranluspec™(ranibizumab) Injection

Thu, 04 Jun 2026 16:39:00 -0400

Ranluspec™ is the only interchangeable biosimilar ranibizumab approved in the United States in both vials and pre-filled syringes

Lupin Receives Approval from U.S. FDA for Ranluspec™(ranibizumab) Injection

Thu, 04 Jun 2026 16:39:00 -0400

Ranluspec™ is the only interchangeable biosimilar ranibizumab approved in the United States in both vials and pre-filled syringes

Lupin Receives Approval from U.S. FDA for Ranluspec™(ranibizumab) Injection

Thu, 04 Jun 2026 16:39:00 -0400

Ranluspec™ is the only interchangeable biosimilar ranibizumab approved in the United States in both vials and pre-filled syringes

Lupin Receives Approval from U.S. FDA for Ranluspec™(ranibizumab) Injection

Thu, 04 Jun 2026 16:39:00 -0400

Ranluspec™ is the only interchangeable biosimilar ranibizumab approved in the United States in both vials and pre-filled syringes

Lupin Receives Approval from U.S. FDA for Ranluspec™(ranibizumab) Injection

Thu, 04 Jun 2026 16:39:00 -0400

Ranluspec™ is the only interchangeable biosimilar ranibizumab approved in the United States in both vials and pre-filled syringes

Lupin Receives Approval from U.S. FDA for Ranluspec™(ranibizumab) Injection

Thu, 04 Jun 2026 16:39:00 -0400

Ranluspec™ is the only interchangeable biosimilar ranibizumab approved in the United States in both vials and pre-filled syringes

Lupin Receives Approval from U.S. FDA for Ranluspec™(ranibizumab) Injection

Thu, 04 Jun 2026 16:39:00 -0400

Ranluspec™ is the only interchangeable biosimilar ranibizumab approved in the United States in both vials and pre-filled syringes

Lupin and Natco Receive Approval from U.S. FDA for Eribulin Mesylate Injection

Wed, 03 Jun 2026 03:11:00 -0400

MUMBAI, India and NAPLES, Fla., June 3, 2026 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) and its alliance partner Natco Pharma Limited (Natco) today announced the approval from the United States Food and Drug Administration (U.S. FDA) for Natco's Abbreviated New Drug Application (ANDA) for Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials.

Eribulin Mesylate Injection, 1

Lupin and Natco Receive Approval from U.S. FDA for Eribulin Mesylate Injection

Wed, 03 Jun 2026 03:11:00 -0400

Eribulin Mesylate Injection, 1

Lupin and Natco Receive Approval from U.S. FDA for Eribulin Mesylate Injection

Wed, 03 Jun 2026 03:11:00 -0400

Eribulin Mesylate Injection, 1

Lupin and Natco Receive Approval from U.S. FDA for Eribulin Mesylate Injection

Wed, 03 Jun 2026 03:11:00 -0400

Eribulin Mesylate Injection, 1

Lupin and Natco Receive Approval from U.S. FDA for Eribulin Mesylate Injection

Wed, 03 Jun 2026 03:11:00 -0400

Eribulin Mesylate Injection, 1

Lupin and Natco Receive Approval from U.S. FDA for Eribulin Mesylate Injection

Wed, 03 Jun 2026 03:11:00 -0400

Eribulin Mesylate Injection, 1

Lupin and Natco Receive Approval from U.S. FDA for Eribulin Mesylate Injection

Wed, 03 Jun 2026 03:11:00 -0400

Eribulin Mesylate Injection, 1